Black Diamond Therapeutics (BDTX) Research & Development: 2019-2021
Historic Research & Development for Black Diamond Therapeutics (BDTX) over the last 3 years, with Dec 2021 value amounting to $19.7 million.
- Black Diamond Therapeutics' Research & Development rose 10.75% to $19.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $87.9 million, marking a year-over-year increase of 93.12%. This contributed to the annual value of $96.8 million for FY2021, which is 100.85% up from last year.
- According to the latest figures from Q4 2021, Black Diamond Therapeutics' Research & Development is $19.7 million, which was down 28.82% from $27.6 million recorded in Q3 2021.
- In the past 5 years, Black Diamond Therapeutics' Research & Development ranged from a high of $27.6 million in Q3 2021 and a low of $3.0 million during Q2 2019.
- In the last 3 years, Black Diamond Therapeutics' Research & Development had a median value of $12.9 million in 2020 and averaged $13.8 million.
- Data for Black Diamond Therapeutics' Research & Development shows a peak YoY spiked of 210.31% (in 2021) over the last 5 years.
- Quarterly analysis of 3 years shows Black Diamond Therapeutics' Research & Development stood at $7.5 million in 2019, then spiked by 138.02% to $17.8 million in 2020, then rose by 10.75% to $19.7 million in 2021.
- Its Research & Development stands at $19.7 million for Q4 2021, versus $27.6 million for Q3 2021 and $22.8 million for Q2 2021.